Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of PF-07293893 in Healthy Adults
NCT05907395Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07293893 in heart failure (HF) (3 cohorts), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events, Number of Participants With Laboratory Test Abnormalities and 2 more. Started Aug 2023; status: completed.
02
Drugs
PF-07293893
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05907395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05907395.